Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
Authors
Keywords
-
Journal
Biology-Basel
Volume 9, Issue 11, Pages 347
Publisher
MDPI AG
Online
2020-10-22
DOI
10.3390/biology9110347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood
- (2020) Anna R Kahkoska et al. BMJ Open Diabetes Research & Care
- Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes
- (2019) Lucy M. Hinder et al. Scientific Reports
- Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
- (2019) Silvio E. Inzucchi et al. DIABETES CARE
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism
- (2019) Stephanie Eid et al. DIABETOLOGIA
- Diabetic neuropathy
- (2019) Eva L. Feldman et al. Nature Reviews Disease Primers
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- (2019) Aaron Y. Kluger et al. Cardiovascular Diabetology
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care
- (2018) P. H. Winocour DIABETIC MEDICINE
- Empagliflozin: A Review in Type 2 Diabetes
- (2018) James E. Frampton DRUGS
- Diabetes and obesity are the main metabolic drivers of peripheral neuropathy
- (2018) Brian C. Callaghan et al. Annals of Clinical and Translational Neurology
- Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
- (2018) Kyung Ae Lee et al. Diabetes & Metabolism Journal
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- (2017) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
- (2017) Eva L. Feldman et al. NEURON
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?
- (2016) Paul D. Rosenblit Cardiovascular Diabetology
- Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review
- (2016) Daniel Shu Wei Ting et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
- (2016) Matthias Kern et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population
- (2016) Brian C. Callaghan et al. JAMA Neurology
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes
- (2015) Junguk Hur et al. DIABETES
- The Maternal Environment Programs Postnatal Weight Gain and Glucose Tolerance of Male Offspring, but Placental and Fetal Growth Are Determined by Fetal Genotype in theLeprdb/+ Model of Gestational Diabetes
- (2015) Raja Nadif et al. ENDOCRINOLOGY
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Obesity, insulin resistance, and type 1 diabetes mellitus
- (2015) Sarit Polsky et al. Current Opinion in Endocrinology Diabetes and Obesity
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Adverse effects and safety of SGLT-2 inhibitors
- (2014) S. Halimi et al. DIABETES & METABOLISM
- Mouse Models of Diabetic Neuropathy
- (2014) P. D. O'Brien et al. ILAR JOURNAL
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- The use of animal models in diabetes research
- (2012) Aileen JF King BRITISH JOURNAL OF PHARMACOLOGY
- Diabetic neuropathy
- (2012) Brian C. Callaghan et al. CURRENT OPINION IN NEUROLOGY
- Identification of Cross-Species Shared Transcriptional Networks of Diabetic Nephropathy in Human and Mouse Glomeruli
- (2012) Jeffrey B. Hodgin et al. DIABETES
- Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy
- (2012) Lucy M. Hinder et al. EXPERIMENTAL NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More